Guardian Pharmacy Reaffirms 2025 Outlook, Issues 2026 Guidance
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Guardian Pharmacy Services, Inc. Class A ( (GRDN) ) has shared an update.
Guardian Pharmacy Services, a major U.S. long-term care pharmacy operator, reaffirmed its 2025 revenue guidance of $1.43 billion to $1.45 billion and adjusted EBITDA guidance of $104 million to $106 million, while issuing an initial 2026 outlook that anticipates revenue of $1.40 billion to $1.42 billion after the impact of Inflation Reduction Act drug-pricing reforms and wholesale acquisition cost reductions. Despite the expected top-line pressure from these mandatory pricing changes, the company projects 2026 adjusted EBITDA of $115 million to $118 million—about 11% year-on-year growth and implying an adjusted EBITDA margin above 8%—and highlighted that its strengthened operating model should allow it to maintain its low double-digit adjusted EBITDA growth trajectory without altering its approach to resident care or facility support; Guardian also disclosed it had completed the year-end acquisition of a single pharmacy in Montana, extending its geographic footprint into a new territory in line with its expansion strategy.
The most recent analyst rating on (GRDN) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Guardian Pharmacy Services, Inc. Class A stock, see the GRDN Stock Forecast page.
Spark’s Take on GRDN Stock
According to Spark, TipRanks’ AI Analyst, GRDN is a Neutral.
Guardian Pharmacy Services shows strong growth potential with increased guidance and strategic acquisitions. However, financial risks due to high leverage and operational inefficiencies, combined with a high P/E ratio, temper the overall attractiveness of the stock.
To see Spark’s full report on GRDN stock, click here.
More about Guardian Pharmacy Services, Inc. Class A
Guardian Pharmacy Services (NYSE: GRDN) is one of the nation’s leading long-term care pharmacy services providers, partnering with long-term care facilities through a locally based model to deliver medications and technology-enabled services that enhance care, improve adherence, reduce costs, and support better clinical outcomes. The company operates a growing network of more than 50 pharmacies across the U.S., serving approximately 204,000 residents as of September 30, 2025.
Average Trading Volume: 310,308
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.92B
See more insights into GRDN stock on TipRanks’ Stock Analysis page.
